Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone undecanoate for men with nonalcoholic fatty liver disease and low testosterone
ACTRN12619000701123Phase 3Recruiting
- Sponsor
- Austin Health
- Start
- Nov 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and Hypoandrogenism (TD) comparing Testosterone undecanoate with Matching placebo (2 arms). Primary endpoint: Percentage change in hepatic steatosis. Started Nov 2020; status: recruiting.
02
Drugs
testosterone undecanoate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)Hypoandrogenism (TD)
Beyond the preview
Go deeper on ACTRN12619000701123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000701123.